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Introduction {#sec005}
============

Liver disease can have various causes, including infection with viruses, such as the hepatitis B virus (HBV) and the hepatitis C virus (HCV), especially in developing countries \[[@pone.0121168.ref001]\]. Interferon gamma (IFN-γ) is a key regulatory cytokine, which plays an important role in antiviral defense by an infected host. IFN-γ can exert antiproliferative and antitumor activity by binding with a specific cell-surface receptor (IFN-γR) \[[@pone.0121168.ref002]\]. IFN-γ is thought to play a major role in combating chronic hepatitis (CH), liver cirrhosis (LC), and hepatocellular carcinoma (HCC)\[[@pone.0121168.ref003]\].

Genetic susceptibility is an important factor in the development of diseases. The *IFN*-*γ* gene on chromosome 12q24 spans approximately 5.4 kb and is composed of four exons, with three intervening regions; many single nucleotide polymorphisms (SNPs) are located in this region \[[@pone.0121168.ref004]\] ([Fig 1](#pone.0121168.g001){ref-type="fig"}). However, only the SNP (+874T/A, rs2430561) of the gene is widely studied. This polymorphism results in the replacement of the T allele with an A allele, which is located at the translation start site in the first intron of the *IFN*-γ gene. The TT genotype is associated with increased IFN production when the immune system responds to stimuli \[[@pone.0121168.ref005]\]. In contrast, the AA and TA genotypes are linked to low IFN production \[[@pone.0121168.ref005]\]. The release of IFN-γ by CD4+ Th1 cells, natural killer cells, and other lymphocytes increases T-cell cytotoxicity and natural killer cell activity and enhances cellular immune responses. It appears that the +874T/A polymorphism can influence IFN-γ expression, and in this way, affects immune response.

![The position of +847A/T (rs2430561) locus and other SNPs in the neighborhood of *IFN-*γ gene on chromosome 12q24(A) and the hypothesis of *IFN-*γ gene polymorphism pathway increase the risk of hepatitis virus-related diseases(B).\
The figure includes the 5'flanking region (white column), exons (dark column) interrupted by introns (gray column) and 3'flanking region. IFNGR, interferon gamma receptor; JAK, Janus kinase; STAT, Signal Transducer and Activator of Transcription; NF, nuclear factor.](pone.0121168.g001){#pone.0121168.g001}

Many studies have mainly focused on the *IFN*-γ +874T/A polymorphism and virus-related disease risk, especially liver diseases, such as CH, LC, and HCC, which are caused by persistent hepatitis virus infection. However, the literature on the impact of the *IFN*-γ gene polymorphism on the risk of hepatitis virus---related diseases has provided contradictory results \[[@pone.0121168.ref006]--[@pone.0121168.ref016]\]. Since the *IFN*-γ +874T/A polymorphism is strongly associated with circulating *IFN*-γ concentrations, it is assumed that this polymorphism might be closely related to the risk of the hepatitis virus---related diseases. Our aim was to examine the association between the *IFN*-γ +874T/A polymorphism and the risk of hepatitis virus-related diseases in published studies using a meta-analysis.

Materials and Methods {#sec006}
=====================

This meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, including the search strategy, selection criteria,data extraction and data analysis \[[@pone.0121168.ref017]\].

Identification of eligible studies {#sec007}
----------------------------------

We used the following terms to search for articles published in Embase, PubMed, and the Cochrane Library up to November 30, 2014: "interferon," "IFN" "polymorphism," "polymorphisms," "mutation," "variant," "hepatitis," "cirrhosis," and "hepatocellular carcinoma." Two investigators (Yifan Sun and Yu Lu) conducted an extensive independent literature search. Articles in reference lists were hand-searched. Only English-language articles and human studies were searched.

Inclusion and exclusion criteria {#sec008}
--------------------------------

The following criteria were used to select suitable studies: (1) case-control or cohort design studies; (2) contained data that could be extracted to calculate the odds ratio (OR), 95% confidence intervals (CIs), and Hardy---Weinberg equilibrium (HWE); (3) stated the DNA genotyping method and source of cases and controls. The following were excluded: review articles, letters, case reports, editorials, conference abstracts, and family-based studies.

Data extraction {#sec009}
---------------

Two investigators (Yifan Sun and Yu Lu) independently extracted data from the included studies. The data included the first author's name, publication date, country, ethnicity, total sample size, virus type and liver disease type, genotyping method, genotype frequencies of cases and controls, source of the case group and control group, age and sex ratio, source of specimens used to determine the genotypes, and the estimated HWE. If the literature did not provide sufficient data, the investigators tried to contact the author to get the original data by email.

In the subgroup analysis, ethnicities from Europe, West Asia, North Africa, and the Americas were categorized as Caucasian and those from East or Southeast Asia as Asian. The hepatitis virus type and liver disease type were also categorized. If the data in the study were related to various liver diseases, the study was treated as a separate study in the meta-analysis. To determine the accuracy of the extracted information, the data extracted by the two investigators were expected to be the same. In cases of a dispute, they checked their data again. If they could not reach an agreement, the dispute was resolved by a third reviewer (Xue Qin).

Quality score assessment {#sec010}
------------------------

Two investigators (Yifan Sun and Shan Li) assessed the quality of the selected studies independently, following the criteria predefined by Thakkinstian et al. \[[@pone.0121168.ref018]\] and used by Ye et al. \[[@pone.0121168.ref019]\]([S1 Table](#pone.0121168.s001){ref-type="supplementary-material"}). The criteria were the sources of the cases and controls, the total sample size, the source of the specimens, and the HWE of the controls. According to the quality score assessment, a study scoring \<10 was considered a "low-quality" study, whereas one with a score ≥10 was classified as a "high-quality" study. The lowest score was 0, and the highest score was 15 \[[@pone.0121168.ref019]\].

Statistical analysis {#sec011}
--------------------

The association between the *IFN*-γ +874T/A polymorphism and hepatitis virus-related diseases was assessed with various comparison models, including an allelic model (A vs. T), a co-dominant model (TA vs. TT and AA vs. TT), a dominant model (TA+AA vs. TT), and a recessive model (AA vs. TA+TT). Because the studies lacked details of the environmental factors, unadjusted ORs and the corresponding 95% CIs were used to measure the strength of the models.

In common with previous studies \[[@pone.0121168.ref020], [@pone.0121168.ref021]\], heterogeneity was assessed with a chi-squared Q test and I-squared statistics. If *P* ~*Q*~\<0.1 or *I* ^*2*^≥50%, the heterogeneity was considered significant. The random-effects model used the DerSimonian and Laird method. Otherwise, the summary OR and the corresponding 95% CI were calculated with a fixed-effects model (the Mantel---Haenszel method). We also conducted a subgroup analysis by ethnicity, genotyping method, source of controls, hepatitis virus type, liver disease type, and quality assessment score. A meta-regression that included the following covariates was performed: ethnicity, genotyping method, source of controls, and quality scores. Covariates with values of *P*\<0.05 were considered the main sources of heterogeneity. Galbraith plot analysis was performed for further exploration of the heterogeneity. Sensitivity analysis was conducted to examine such influence by removing studies one by one and recalculating the pooled OR and 95% CI.

A Begg's funnel plot and an Egger's test were used to investigate publication bias in the meta-analysis. *P*\<0.05 indicated that the result was statistically significant.

All tests in this meta-analysis were conducted with STATA software (version 12.0; Stata Corporation, College Station, Texas, USA).

Results {#sec012}
=======

Literature selection and study characteristics {#sec013}
----------------------------------------------

Based on the search terms, 17 articles, which included 24 case-control studies containing 2,607 cases and 2,896 controls, were identified as suitable for a meta-analysis \[[@pone.0121168.ref003], [@pone.0121168.ref006], [@pone.0121168.ref007], [@pone.0121168.ref009], [@pone.0121168.ref012]--[@pone.0121168.ref014], [@pone.0121168.ref016], [@pone.0121168.ref022]--[@pone.0121168.ref030]\] ([Fig 2](#pone.0121168.g002){ref-type="fig"}). The primary characteristics of the 24 studies are shown in [Table 1](#pone.0121168.t001){ref-type="table"}. Nine of the articles focused on Caucasians and eight on Asians. Sixteen studies focused on HBV-related diseases, five on HCV-related diseases, one on HDV-related disease, one on HEV-related disease, and one on mixed virus (HBV and HCV)-related HCC. When the articles were categorized by liver disease, two focused on HBV infection (only HBV carrier), nine focused on chronic hepatitis B (CHB), and seven focused on LC/HCC. The genotyping methods included the polymerase chain reaction-amplification refractory mutation system (ARMS-PCR), polymerase chain reaction-sequence specific primers (PCR-SSP), competitively differentiated-polymerase chain reaction (CD-PCR), and DNA sequencing. The HWE of the control population was calculated according to the genotypes. The control population did not fall into HWE in three articles \[[@pone.0121168.ref013], [@pone.0121168.ref025], [@pone.0121168.ref029]\]. According to the quality scores, 13 articles were "high-quality" studies. The source of the control population was divided into hospital based and population based.

![Flow diagram of included studies for this meta-analysis.](pone.0121168.g002){#pone.0121168.g002}
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###### Characteristics of Studies Included in This Review.

![](pone.0121168.t001){#pone.0121168.t001g}

  Study        Year   Country       Enthicity   Liver virus   Liver diseases   Genotyping method   Source of control   Case sequence   Control sequence   *P* [\*](#t001fn002){ref-type="table-fn"} (HWE)   Quality scores                             
  ------------ ------ ------------- ----------- ------------- ---------------- ------------------- ------------------- --------------- ------------------ ------------------------------------------------- ---------------- --------- ----- --------- ----
  Teixeira     2013   Brazil        Caucasian   HBV           HCC              SSP-PCR             PB                  40              50                 21                                                79               82        41    0.024     11
  Arababadi    2011   Iran          Caucasian   HBV           HBV infection    AMRS-PCR            PB                  18              25                 14                                                28               47        25    0.554     9
  Basturk      2008   Turkey        Caucasian   HBV           CHB              SSP-PCR             PB                  19              23                 8                                                 26               24        10    0.282     10
  Ben-Ari      2003   Israel        Caucasian   HBV           CHB              SSP-PCR             HB                  33              13                 10                                                18               24        6     0.644     10
  Ben-Ari      2003   Israel        Caucasian   HBV           LC/HCC           SSP-PCR             HB                  17              10                 4                                                 18               24        6     0.644     10
  Bouzgarrou   2009   Tunisia       Caucasian   HCV           HCV infection    SSP-PCR             PB                  22              10                 10                                                33               47        33    0.074     11
  Bouzgarrou   2010   Tunisia       Caucasian   HCV           LC/HCC           SSP-PCR             PB                  17              21                 20                                                33               47        33    0.074     11
  Cheong       2006   South Korea   Asian       HBV           CHB              Sequencing          HB                  314             94                 5                                                 151              47        3     0.760     11
  Conde        2013   Brazil        Caucasian   HBV           CHB              SSP-PCR             PB                  27              19                 7                                                 51               37        9     0.547     11
  Falleti      2007   Italy         Caucasian   HCV           LC/HCC           AMRS-PCR            PB                  12              28                 10                                                30               51        15    0.382     11
  Gao          2009   China         Asian       HBV           HBV infection    SSP-PCR             PB                  25              35                 9                                                 14               53        7     \<0.000   8
  Gao          2009   China         Asian       HCV           HCV infection    SSP-PCR             PB                  23              27                 5                                                 14               53        7     \<0.000   8
  Karatayli    2014   Turkey        Caucasian   HDV           CHD              SSP-PCR             HB                  9               33                 22                                                11               28        15    0.753     9
  Karatayli    2014   Turkey        Caucasian   HBV           CHB              SSP-PCR             HB                  37              47                 34                                                11               28        15    0.753     9
  Korachi      2013   Turkey        Caucasian   HBV           CHB              Sequencing          PB                  38              57                 5                                                 16               56        27    0.147     12
  Korachi      2013   Turkey        Caucasian   HCV           CHC              Sequencing          PB                  20              50                 30                                                16               56        27    0.147     12
  Mishra       2011   India         Asian       HEV           HEV infection    Sequencing          PB                  24              84                 28                                                90               178       106   0.370     12
  Nieters      2004   China         Asian       Mixed         HCC              SSP-PCR             HB                  86              155                94                                                164              \>0.200   10              
  Saxena       2014   India         Asian       HBV           HCC/LC           SSP-PCR             PB                  36              56                 27                                                52               77        17    0.180     12
  Saxena       2014   India         Asian       HBV           CHB              SSP-PCR             PB                  31              20                 13                                                52               77        17    0.180     12
  Srivastava   2014   India         Asian       HBV           LC/HCC           SSP-PCR             PB                  44              53                 29                                                14               55        7     \<0.000   9
  Srivastava   2014   India         Asian       HBV           CHB              SSP-PCR             PB                  32              61                 13                                                14               55        7     \<0.000   9
  Peng         2007   China         Asian       HBV           CHB              CD-PCR              HB                  247             89                 4                                                 65               33        2     0.545     10
  Migita       2005   Japan         Asian       HBV           HCC              SSP-PCR             HB                  41              7                  0                                                 157              31        0     0.218     11

Abbreviation: CHB, chronic hepatitis B;CHD, chronic hepatitis D; LC, liver cirrhosis; HCC, hepatocellular carcinoma; HBV /HCV/HEV infection, only hepatitis virus carriers; SSP-PCR, polymerase chain reaction-sequence specific primers; AMRS-PCR, polymerase chain reaction-amplification refractory mutation system; CD-PCR, competitively differentiated-polymerase chain reaction; HB, Hospital-based; PB, Population-based; Mixed, HBV and HCV infection; HWE, Hardy---Weinberg equilibrium.

\**P* value of HWE of control

Allele frequencies in different ethnicities {#sec014}
-------------------------------------------

Allele frequencies in different ethnicities were calculated according to the original data of the studies. The *IFN*-γ +874T/A loci A allele had a higher representation in the controls of the Asian group than in the Caucasian group (65.5% vs. 55.6%, ***χ*** ^**2**^ = 47.07,*P* = 0.000). On average, the frequency of AA, TA, and TT as a proportion of 1 was 0.38, 0.41, and 0.21 respectively in the Asian population controls and 0.32, 0.48, and 0.20 in the Caucasian population; a significant difference was observed between the two ethnicities (***χ*** ^**2**^ = 14.467, *P* = 0.001), as well as in the cases (***χ*** ^**2**^ = 56.53, *P* = 0.000). The allele frequencies in the African group were not analyzed because of the sample size was too small.

Meta-analysis results {#sec015}
---------------------

The results of the meta-analysis of the *IFN*-γ +874T/A polymorphism and hepatitis virus---related disease risk are listed in [Table 2](#pone.0121168.t002){ref-type="table"}. In the pooled analysis using the random-effects model, there was a significant increased risk of hepatitis virus-related disease in the recessive model (AA vs. TT+TA: OR = 1.350, 95% CI = 1.101--1.657, *P* = 0.004, *I* ^*2*^% = 54.3, and *P* ~*Q*~ = 0.001 for heterogeneity; see [Fig 3](#pone.0121168.g003){ref-type="fig"}).

![Forest plot for the association between *IFN-*γ +874T/A polymorphism and hepatitis virus-related diseases risk stratified by ethnicity in a recessive model (AA vs. TT+TA) using a random-effects mode.\
The squares and horizontal lines correspond to the study-specific OR and 95%CI. The diamond represents the summary OR and 95%CI.](pone.0121168.g003){#pone.0121168.g003}
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###### Meta-analysis of interferon gamma +874T/A polymorphisms and hepatitis virus-related diseases.

![](pone.0121168.t002){#pone.0121168.t002g}

  Group                   N    A vs. T                   AA vs. TT   TA vs. TT             AA vs. TT+TA   N[\*](#t002fn004){ref-type="table-fn"}   AA+TA vs. TT                                                                
  ----------------------- ---- ------------------------- ----------- --------------------- -------------- ---------------------------------------- -------------- ------------------------- ------- ---- --------------------- -------
  **Overall**             23   1.121(0.993--1.265)       0.022       1.106(0.845--1.446)   0.032          0.789(0.597--1.042)                      0.003          **1.284(1.126--1.464)**   0.001   23   0.914(0.738--1.133)   0.031
  **Ethnicity**                                                                                                                                                                                                                
  Asian                   10   1.082(0.953--1.228)       0.246       0.906(0.659--1.246)   0.464          0.634(0.363--1.105)                      0.002          **1.407(1.035--1.911)**   0.005   10   0.790(0.559--1.117)   0.051
  Caucasian               13   1.134(0.931--1.380)       0.008       1.210(0.820--1.787)   0.013          0.944(0.747--1.194)                      0.137          1.306(0.979--1.743)       0.017   13   1.052(0.846--1.308)   0.107
  **Virus-related**                                                                                                                                                                                                            
  HBV                     15   **1.196(1.065--1.343)**   0.169       1.262(0.878--1.815)   0.067          0.763(0.503--1.158)                      0.004          **1.486(1.195--1.849)**   0.053   14   0.931(0.651--1.333)   0.020
  HCV                     5    1.144(0.845--1.550)       0.078       1.182(0.783--1.785)   0.275          0.766(0.525--1.117)                      0.999          1.488(0.863--2.565)       0.030   5    0.909(0.643--1.285)   0.869
  **Liver disease**                                                                                                                                                                                                            
  CHB                     9    **1.245(1.009--1.538)**   0.045       1.424(0.791--2.564)   0.012          0.861(0.476--1.557)                      0.006          **1.498(1.133--1.980)**   0.070   9    1.063(0.620--1.821)   0.011
  LC/HCC                  7    0.914(0.774--1.079)       0.547       0.748(0.528--1.059)   0.581          0.623(0.386--1.007)                      0.081          1.094(0.782--1.530)       0.068   7    0.751(0.550--1.024)   0.186
  **Source of control**                                                                                                                                                                                                        
  HB                      15   **1.221(1.036--1.438)**   0.652       1.259(0.821--1.933)   0.851          0.692(0.469--1.020)                      0.880          **1.475(1.190--1.828)**   0.106   15   0.919(0.709--1.191)   0.988
  PB                      8    1.070(0.906--1.265)       0.006       1.058(0.738--1.517)   0.004          0.827(0.567--1.205)                      0.000          1.235(0.940--1.622)       0.002   8    0.915(0.658--1.273)   0.001
  **Score≥10**            16   1.110(0.944--1.304)       0.006       1.111(0.771--1.601)   0.006          0.889(0.621--1.274)                      0.003          1.213(0.964--1.526)       0.006   16   0.990(0.753--1.303)   0.014

Abbreviation: N, number of studies; OR, odds ratio; CI, confidence interval; *P* ~***Q*,**~ chi-squared Q test value, CHB, chronic hepatitis B;LC, liver cirrhosis;

HCC, hepatocellular carcinoma; HB, Hospital-based; PB, Population-based; Score, quality scores

^▲^If *P* ~*Q*~\<0.1,using a random-effects model; If *P* ~*Q*~≥0.1,using a fixed- effects model.

\*number of studies: AA+TA vs. TT mode

For the recessive model, the results of the subgroup analysis showed that the *IFN*-γ +874T/A polymorphism significantly increased the risk of hepatitis virus-related disease in Asians (OR = 1.407, 95% CI = 1.035--1.911, *P* = 0.029, *I* ^*2*^% = 61.9 and *P* ~*Q*~ = 0.005 for heterogeneity; see [Fig 3](#pone.0121168.g003){ref-type="fig"}). Similar results were found for the HBV---related diseases group (OR = 1.486, 95% CI = 1.195--1.849, *P* = 0.000, *I* ^*2*^% = 40.4, and *P* ~*Q*~ = 0.053 for heterogeneity; see [Fig 4](#pone.0121168.g004){ref-type="fig"}), CHB patient group (OR = 1.498, 95%CI = 1.133--1.980, *P* = 0.005, *I* ^*2*^% = 44.8, and *P* ~*Q*~ = 0.070 for heterogeneity), SSP-PCR method group (OR = 1.449,95%CI = 1.124--1.867, *P* = 0.004, *I* ^*2*^% = 53.8, and *P* ~*Q*~ = 0.007 for heterogeneity), and hospital-based population (OR = 1.475, 95% CI = 1.126--1.464, P = 0.000, *I* ^*2*^% = 39.3, and *P* ~*Q*~ = 0.106 for heterogeneity).

![Forest plot for the association between *IFN-*γ +874T/A polymorphism and hepatitis virus-related diseases risk stratified by hepatitis virus type in a recessive model (AA vs. TT+TA) using a random-effects mode.\
The squares and horizontal lines correspond to the study-specific OR and 95%CI. The diamond represents the summary OR and 95%CI.](pone.0121168.g004){#pone.0121168.g004}

For the allelic model (allele A vs. allele T), the *IFN*-γ +874T/A polymorphism significantly increased the risk of hepatitis virus---related disease in the HBV-related diseases group (OR = 1.196,95%CI = 1.065--1.343, *P* = 0.003, *I* ^*2*^% = 25.9,and *P* ~*Q*~ = 0.169 for heterogeneity). Similar results were observed for the CHB patient group (OR = 1.245, 95% CI = 1.009--1.538, *P* = 0.004, *I* ^*2*^% = 49.0, and *P* ~*Q*~ = 0.045 for heterogeneity) and the hospital-based population (OR = 1.221, 95%CI = 1.036--1.438, *P* = 0.017, *I* ^*2*^% = 0.0, and *P* ~*Q*~ = 0.652 for heterogeneity).

Other results indicated a lack of statistical significance between the *IFN*-γ +874T/A polymorphism and hepatitis virus---related disease risk ([Table 2](#pone.0121168.t002){ref-type="table"})

Heterogeneity analysis {#sec016}
----------------------

All the models revealed statistical heterogeneity for the *IFN*-γ +874T/A polymorphism in the overall population, with *I* ^*2*^ values of heterogeneity greater than 50% and *P* ~*Q*~ values lower than 0.100. Heterogeneity still existed in some studies following the subgroup analysis according to ethnicity, virus genotyping method, sources of control, quality score assessment, hepatitis virus type, and liver disease type. A meta-regression of the sources of heterogeneity revealed that the genotype methods were the main sources of heterogeneity (*P* = 0.005, 95% CI = 0.299--1.470). A Galbraith plot analysis confirmed that the studies by Korachi et al. (HBV), Gao et al. (HCV), Bouzgarrou et al. (HCV), and Mishra et al. (HEV) were responsible for the heterogeneity in the recessive model. After these four studies were excluded, the summary OR value did not change significantly (OR = 1.251, 95% CI = 1.034--1.513, *P* = 0.021, *I* ^*2*^% = 25.8, *P* ~*Q*~ = 0.078 for heterogeneity). In the allelic model, the studies by Korachi et al. (HBV) \[[@pone.0121168.ref027]\] and Saxena et al. (HCC/LC) \[[@pone.0121168.ref003]\] were the outliers. In the co-dominant model and the dominant model, the summary OR value did not change significantly after these two studies were excluded. However, following their exclusion, the *I* ^*2*^ values were lower than 50%, and the *P* ~*Q*~ value was larger than 0.10 (data not shown).

Sensitivity analysis {#sec017}
--------------------

The control groups in the studies by Teixeira et al. \[[@pone.0121168.ref029]\], Gao et al. \[[@pone.0121168.ref025]\], and Srivastava et al. \[[@pone.0121168.ref014]\] were out of HWE ([Table 1](#pone.0121168.t001){ref-type="table"}), and these three studies were excluded to perform a sensitivity analysis of the pooled ORs for the *IFN-γ* (+874T/A) polymorphism. Further sensitivity analysis was performed by excluding the studies by Karatayli et al. \[[@pone.0121168.ref026]\] and Mishra et al. \[[@pone.0121168.ref012]\], in which the study virus types were HDV and HEV, respectively. Three articles that used the DNA sequencing method to obtain the genotype were also excluded one by one \[[@pone.0121168.ref007], [@pone.0121168.ref012], [@pone.0121168.ref027]\]. Finally, the corresponding pooled ORs were not qualitatively altered with or without including these studies (data not shown).

Publication bias {#sec018}
----------------

A Begg's funnel plot and an Egger's test were used to investigate the publication bias in the meta-analysis ([Fig 5](#pone.0121168.g005){ref-type="fig"}). No significant publication bias was detected with the funnel plot in the overall population in the recessive model. The statistical results of the Egger's test also provided evidence of funnel plot symmetry (*P* ~*Egger's*~ test = 1.840; *P* = 0.08).

![Begg's funnel plot for contrast in a recessive model (AA vs. TT+TA).\
Each point represents a separate study for the indicated association. Size graph symbol by weights. *LogOR* natural logarithm of OR. Horizontal line mean effect size.](pone.0121168.g005){#pone.0121168.g005}

Discussion {#sec019}
==========

Various environmental and dietary factors are responsible for liver diseases, but hepatitis infection is the main cause of CH, LC, and HCC \[[@pone.0121168.ref031]\]. The association between the *IFN*-γ +874T/A polymorphism and the risk of hepatitis virus---related diseases has been studied extensively because of the importance of IFN-γ in immune responses \[[@pone.0121168.ref003], [@pone.0121168.ref009], [@pone.0121168.ref013], [@pone.0121168.ref016], [@pone.0121168.ref025], [@pone.0121168.ref029]\]. However, previous studies provided inconsistent results. To clarify this issue, we conducted a meta-analysis, and the results showed that there was a significant association between the *IFN*-γ +874T/A polymorphism and risk of hepatitis virus---related disease in the pooled analysis in the recessive model, with the +874 AA genotype associated with a 1.350-fold increased risk of hepatitis virus related---disease, especially in Asian and HBV---related diseases

The results indicate that the *IFN*-γ +874T/A polymorphism may play an important role in hepatitis virus---related disease. The following pathways are considered the main way in which the *IFN*-γ +874T/A polymorphism affects the development of hepatitis virus infection. First, the *IFN*-γ +874T/A genotype TT, which produces a high level of IFN-γ, aids the host's antiviral defense system. In contrast, the AA and TA genotypes result in low *IFN*-γ production, potentially increasing the risk of hepatitis virus infection \[[@pone.0121168.ref032]\]. Second, as noted earlier, IFN-γ binds to a specific cell-surface receptor (IFN-γR), which plays a significant role in multiple types of cancers and stimulates cell signaling pathways (JAK-STAT). The *IFN*-γ +874T/A polymorphism leads to dysfunction of IFN-γR, potentially increasing the risk of liver diseases \[[@pone.0121168.ref002]\]. In addition, the DNA sequence containing the +874 T allele is the specific binding site for the nuclear factor Kappa B(NF-*κ*B) transcription factor. If the NF-κB pathway is affected, it may lead to oxidative damage, which can also increase the risk of LC and HCC \[[@pone.0121168.ref032]\]. The possible pathway of the *IFN*-*γ* polymorphism increase in hepatitis virus---related diseases risk is shown in [Fig 1](#pone.0121168.g001){ref-type="fig"}.

The stratified analysis by ethnicity in the present study suggested that the *IFN*-γ +874T/A polymorphism influenced the risk of hepatitis virus-related diseases in Asians but not in Caucasians. Many factors may contribute to this finding. First, hepatitis virus related---disease is a complex entity, with multiple determinants other than virus infection, such as diet and the environment. Some studies noted significant gene---gene and gene---environmental interactions in patients with hepatitis virus related---diseases \[[@pone.0121168.ref033]--[@pone.0121168.ref035]\]. Second, as shown in previous studies, the gene frequency of the *IFN-*γ +874T/A polymorphism varies in ethnicities \[[@pone.0121168.ref036], [@pone.0121168.ref037]\], and the Asian population had a higher rate of the A allele than that in the Caucasian population in our study. Third, the inclusion of study subjects from different populations, together with the various genotyping methods and the different sample sizes used in these studies, means it is not possible to reach a definitive conclusion, and the results remain conflicting.

The subgroup analysis showed that the significant results are mainly reflected in the HBV---related group. Evidence suggests that IFN-γ can suppress viral replication/clear HBV without causing liver injury, the non-cytolytic HBV suppression effect of IFN-γ is believed to have an important role in the control of HBV viral activity in patients with CHB \[[@pone.0121168.ref038]\]. Regarding CHB, *IFN-γ* +874 was seen to play a functional role in relation to viral load, consistent with its known role inhibiting and replicating of HBV-infected cells \[[@pone.0121168.ref016]\]. IFN-γ can also induce expression of HLA class II \[[@pone.0121168.ref039]\], and a genome-wide association study (GWAS) showed that HLA contributes to the risk of persistent HBV infection \[[@pone.0121168.ref040]\].

As we now known, the *IFN*-γ +874T/A TT genotype produces a high level of IFN-γ, and the AA and TA genotypes result in low IFN-γ production. Thus we can suppose that the AA+TA vs. TT model may have significant association in the analysis. However, the ORs of AA vs. TT+TA and AA+TA vs. TT are opposite in our meta-analysis. These confusing results suggested that the T allele is a protective gene in liver disease; moreover, this allele has more power than the A allele, therefore, only the population with the AA genotype has higher risk of hepatitis virus-related liver disease. Indeed, similar results happened in the association between the *IFN*-γ +874T/A polymorphism and cervical cancer with human papillomavirus (HPV) infection \[[@pone.0121168.ref041]\] and leprosy caused by *Mycobacterium leprae*\[[@pone.0121168.ref042]\]. A meta-analysis also indicated that the +874 T allele of *IFN*-γ showed a protective significant association with tuberculosis susceptibility \[[@pone.0121168.ref043]\].

Studies have also reported the role of the *IFN*-γ gene in the response to drug treatment in cancer \[[@pone.0121168.ref044]\]. Sarvari et al. \[[@pone.0121168.ref013]\] indicated that the +2109 locus of the *IFN*-γ gene, which is also the specific binding site for NF-*κ*B similar to the +874 locus, influenced HCV therapy. Moreover, Oxenkrug et al. \[[@pone.0121168.ref045]\] found that T alleles at the +874 locus of the *IFN*-γ gene were a risk factor in depressed patients with HCV who were treated with IFN-alpha. The *IFN-*γ gene polymorphism may further affect the development of HCC and the response to cancer drugs by increasing the risk of hepatitis virus-related diseases, although we did not observe a significant association between the (+874T/A) polymorphism and HCC risk in this study, which is worthy of further investigation in the future.

We noticed that the meta-analysis by Ge et al.\[[@pone.0121168.ref046]\] also suggested that the +874T/A polymorphism may not contribute to HCC susceptibility with three studies, which was verified by our meta-analysis with six studies. In addition, Sun et al. \[[@pone.0121168.ref047]\] also performed a meta-analysis of the +874T/A polymorphism and CHB risk with five studies, and their results indicated the TT genotype and the T allele reduce the risk of chronic HBV infection in Asian individuals, which was similar to our meta-analysis of nine studies. However, we did not observed a significant association in co-dominant models. These differences may be because more studies were involved in our study, therefore; therefore, we believe our results are more robust with more statistical power.

Heterogeneity is the most common problem when explaining the results of a meta-analysis. In the current meta-analysis, we assessed heterogeneity using various statistical methods, including subgroup analysis, meta-regression, and Galbraith plot analysis. Finally, we concluded that the heterogeneity in the meta-analysis was due to the genotyping method, mixed infection, and various virus types. Sensitivity analysis was performed by excluding the studies not in HWE. The studies of HDV infection and HEV infection and those that used different genotyping methods, especially the DNA sequencing method, were also excluded one by one. The corresponding pooled OR value did not differ significantly from that of the overall meta-analysis. However, a Begg's funnel plot and an Egger's test (*P*\>0.05) showed no publication bias. Therefore, we consider that the results are credible, although there are some confounding factors in the articles.

GWASs have evolved over the last 10 years into a powerful tool for investigating the genetic architecture of human disease. Recently, many GWASs determined that SNPs at *HLA-DPA1*, *HLA-DPB1*, *HLA-DQB1--HLA-DQA2* and *HLA-DQB2* are associated with chronic HBV infection in Japanese and Korean populations \[[@pone.0121168.ref040], [@pone.0121168.ref048], [@pone.0121168.ref049]\], and Hu et al. identified two new loci associated with chronic HBV infection: rs3130542 at 6p21.33 and rs4821116 at 22q11.21 in Han Chinese \[[@pone.0121168.ref050]\]. In addition, rs17401966 in *KIF1B* on chromosome 1p36.22 locus confers susceptibility to HBV-related HCC \[[@pone.0121168.ref051]\]. Our results suggested that rs2430561 in *IFN*-γ on chromosome 12q24 contributes to susceptibility to HBV-related diseases based on traditional genotyping methods, and these results have motivated us to carry out a GWAS focus on the SNPs on chromosome 12 to discover novel susceptibility loci for HBV-related diseases in the future.

Several limitations of the present meta-analysis should be considered when interpreting the results. First, most of the included studies had small sample sizes, which led to insufficient statistical power to explore the interaction between the *IFN-*γ +874T/A polymorphism and hepatitis virus-related diseases. The lack of association in the other ethnicity or genetic model may be most likely because of insufficient studies. Further studies on this topic in different ethnicities are expected to be conducted to strengthen our results. Second, because a lack in the original data of the reviewed studies, a more precise analysis could not conducted of individual information including other covariates such as age and sex. In spite of these, our meta-analysis had some advantages. First, a substantial number of cases and controls were pooled from different studies, which greatly increased the statistical power compared with individual studies. Second, the results of the sensitivity analyses were not materially altered and did not draw different conclusions, indicating that our results were moderately robust.

Conclusion {#sec020}
==========

In summary, this meta-analysis indicated that the *IFN-*γ +874T/A polymorphism increases the risk of hepatitis virus---related diseases, especially in Asians and HBV-related disease. We expect more relevant studies to be published on this topic in the future to strengthen our conclusion, as it remains a topic of concern and interest.
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